Form 4: Kiniksa Pharmaceuticals Executive Trades Class A Shares

Michael R. Megna, Chief Accounting Officer at Kiniksa Pharmaceuticals International, plc, reported a transaction involving Class A Ordinary Shares.

Summary

• Michael R. Megna, Chief Accounting Officer at Kiniksa Pharmaceuticals International, plc, reported a transaction on April 9, 2026.
• The transaction involved the disposal of 6,625 Class A Ordinary Shares at a price of $46.69 per share.
• Following this transaction, Megna beneficially owns 27,418 Class A Ordinary Shares directly.
• This transaction was executed under a Rule 10b5-1 trading plan established on May 24, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine executive stock transaction executed under a pre-established plan, rather than a reflection of company performance or strategic shifts.

Negatives

• Disposal of 6,625 Class A Ordinary Shares by a key executive.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Kiniksa Pharmaceuticals, are standard disclosures for executive stock transactions. The use of a 10b5-1 plan indicates a pre-arranged trading strategy, often employed by executives to diversify holdings or manage personal finances in a way that avoids insider trading concerns.

Stakeholder Impact

• Shareholders: The disposal of shares by an executive may be observed, but the use of a 10b5-1 plan mitigates concerns about insider trading. The remaining beneficial ownership by the executive is noted.

Key Dates

Keywords

Kiniksa Pharmaceuticals, KNSA, Form 4, Insider Trading, Class A Ordinary Share, 10b5-1 plan, Michael R. Megna